摘要
目的微小RNA（microRNA，miRNA）-21在肾癌组织中高表达，充当癌基因，而大量研究发现血清中特异miRNA与相应的癌组织中表达量趋向一致，而血清标本安全易取。本研究旨在验证血清中miR一21在肾透明细胞癌（renalclear cell carcinoma，cRCC）血清中的表达，术后的变化并探讨其临床应用价值。方法新疆医科大学第一附属医院2013—02—01—2014—07—30收集30例cRCC患者术前血清作为肾癌术前组，平均年龄（52士11）岁。肿瘤直径≤4cm17例，〉4cm13例。Fuhrman分级：Ⅰ～Ⅱ级18例，Ⅲ级12例。对应术后1个月血清作为肾癌术后组。另收集同期该院30例健康体检者血清作为对照组，平均年龄（47±9）岁。利用Real～timePCR技术检测miR-21在肾癌术前组、术后组、对照组血清中的表达量，并分析其临床应用价值。结果对照组血清中miR-21相对表达量为0．70（0．52～3．60），肾癌术前组表达量为8．34（3．66～17．27），肾癌术后组表达量为0．68（0．47～1．07）。与对照组比较，肾癌术前组miR-21表达量显著上调，差异有统计学意义，Z=-4．778，P=0．001；肾癌术后组表达量差异无统计学意义，z=-1．135，P=0．256。与术前组比较，术后组表达量明显下调，差异有统计学意义，z=-3．124，P=0．002。依据miR-21在eRCC患者与健康人血清中表达量不同，利用受试者工作特征受试者工作特征（receiver operating characteristic，ROC）曲线法分析，曲线下面积（area under the curve，AUC）=0．865（95％CI：0．766～0．965，P=0．001），敏感性为77．3％，特异性为96．4％。结论在cRCC患者血清中miR-21呈现高表达，根据R0c分析结果已达到临床应用价值，是cRCC可选的诊断分子标志物。miR-21在切除肿瘤组织后表达量下降，有望用于疗效评估。
OBJECTIVE Mandy studies have found that miR-21 expression is up-regulated and acts as oncogene in renal malignant tumor tissue and special serum microRNAs expression levels tend to similar with tumor tissue. This study aimed to detect serum miR-21 expression levels before and after surgery in patients with renal clear cell carcinoma（cRCC） and analyze its clinical values. METHODS A total of 30 serum samples from patients with cRCC were collected before surgery and after a month of surgery in First Affiliated Hospital of Xinjiang Medical University during the period of February 1 of 2013 to July 30 of 2014. The study included 30 healthy controls. Serum miR-21 expression levels were performed using real-time PCR. RESULTS The medium of serum miR-21 expression levels were 0.70（interquartile range, IQR 0. 52-3. 60） in heathy controls, 8.34（IQR 3.66- 17.27） in pre-operative group and 0.68（IQR 0.47- 1.07） in postoperative group. Serum miR-21 levels in pre-operative group（medium 8. 34） were significantly increased compared with healthy controls （medium 0.70, Z=-4. 778,P=0. 001）. Serum miR-21 levels in post-operative group （medium 0. 68） had no statistically differences compared with healthy controls（medium 0. 70, Z=-1. 135, P= 0. 256）. Serum miR 21 levels in post-operative group（medium 0.68） were significantly reduced compared with pre-operative group（medium 8.34, Z=-3.124, P=0.002）. SerummiR-21 levels yielded AUC of 0. 865（95% CI：0. 766-0. 965,P=0. 001） with 77.3% of sensitivity and 96.4% of specificity. CONCLUSIONS Serum miR-21 levels in patients with cRCC were signifi cantly increased, while its levels were significantly decreased after operative. The outcome suggests that serum miR-21 level is closely related with cRCC. The miR-21 can be regarded as a potential molecular marker in eRCC.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2016年第7期441-445,共5页
Chinese Journal of Cancer Prevention and Treatment
基金
新疆维吾尔自治区自然科学基金重大项目(2013211A101)
